TOVEDESO

This brand name is authorized in Germany, Spain, Croatia

Active ingredients

The drug TOVEDESO contains one active pharmaceutical ingredient (API):

1 Desfesoterodine
UNII 90Y3ELK3FB - DESFESOTERODINE SUCCINATE

Desfesoterodine is a competitive, specific muscarinic receptor antagonist. It is the primary active metabolite of fesoterodine, and regarded as main active pharmacological principle of fesoterodine; fesoterodine is considered as prodrug of desfesoterodine. The affinity of desfesoterodine for the muscarinic receptors is 2 orders of magnitude greater than that of fesoterodine.

Read about Desfesoterodine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TOVEDESO Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
G04BD13 G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut fรผr Arzneimittel und Medizinprodukte Identifier(s): 12447982, 12447999, 12448013, 12448042, 13754829, 13754835
Country: ES Centro de informaciรณn online de medicamentos de la AEMPS Identifier(s): 82434, 82435

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.